Sio Gene Therapies Inc.
NASDAQ:SIOX
0.415 (USD) • At close September 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 53.399 | 24.903 | 47.11 | 87.552 | 141.412 | 134.778 | 76.644 | 0 |
| General & Administrative Expenses
| 18.163 | 17.294 | 22.061 | 39.466 | 71.906 | 45.721 | 56.518 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 18.163 | 17.294 | 22.061 | 39.466 | 71.906 | 45.721 | 56.518 | 0 |
| Other Expenses
| -0.039 | 10.359 | 1.358 | 5.616 | 0.211 | -0.369 | 133.162 | 0 |
| Operating Expenses
| 71.562 | 42.197 | 69.171 | 127.018 | 213.318 | 180.499 | 133.162 | 0 |
| Operating Income
| -72.267 | -34.304 | -67.813 | -127.018 | -213.318 | -180.499 | -133.162 | 0 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.639 | 1.667 | -4.377 | 5.616 | 0.211 | -0.369 | 0 | 0 |
| Income Before Tax
| -71.628 | -32.637 | -72.19 | -128.932 | -220.652 | -182.011 | -133.162 | 0 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.259 | -0.212 | 0.438 | 0.133 | 0.921 | -1.06 | -0.017 | 0 |
| Net Income
| -71.887 | -32.425 | -72.628 | -129.065 | -221.573 | -180.951 | -133.145 | 0 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.98 | -0.62 | -2.93 | -8.02 | -16.51 | -14.6 | -11.28 | 0 |
| EPS Diluted
| -0.98 | -0.62 | -2.93 | -8.02 | -16.51 | -14.6 | -11.28 | 0 |
| EBITDA
| -71.601 | -31.838 | -64.719 | -121.402 | -210.024 | -180.868 | -133.148 | 0 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |